Comparative Pharmacology
Head-to-head clinical analysis: KERYDIN versus KETOZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERYDIN versus KETOZOLE.
KERYDIN vs KETOZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
Ketoconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This leads to increased membrane permeability and cell death.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Terminal elimination half-life is approximately 2 hours (range 1.5–3.5 hours). Clinically, duration of antifungal effect extends beyond plasma half-life due to persistent tissue levels.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Primarily hepatic metabolism; renal excretion of unchanged drug <1%. Biliary/fecal excretion accounts for ~20-35% of metabolites.
Category C
Category C
Antifungal
Antifungal